Pictet Asset Management
ELVN icon

Pictet Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Pictet Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59M Buy
1,161,784
+232,240
+25% +$9.86M 0.06% 306
2026
Q1 		$36.4M Sell
929,544
-373,691
-29% -$10.4M 0.04% 376
2025
Q4 		$20.1M Sell
1,303,235
-94,852
-7% -$1.89M 0.02% 536
2025
Q3 		$28.6M Buy
1,398,087
+430,585
+45% +$8.68M 0.03% 443
2025
Q2 		$19.4M Hold
967,502
– – 0.02% 514
2025
Q1 		$19M Sell
967,502
-4,791
-0.5% -$103K 0.02% 510
2024
Q4 		$21.9M Buy
972,293
+135,969
+16% +$3.52M 0.02% 478
2024
Q3 		$21.4M Buy
836,324
+58,215
+7% +$1.35M 0.02% 481
2024
Q2 		$18.2M Buy
+778,109
New +$16.4M 0.02% 489

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Pictet Asset Management's ELVN Position: Q2 2026 in Review

Pictet Asset Management increased its Enliven Therapeutics (ELVN) stake by 25% in Q2 2026, buying an estimated $9.86M and bringing the position to 1,161,784 shares worth $59M. The position accounts for 0.06% of the portfolio, ranked #306.

Pictet Asset Management first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Pictet Asset Management held 1,161,784 shares of Enliven Therapeutics worth $59M as of Q2 2026.
  • Pictet Asset Management bought 232,240 Enliven Therapeutics shares in Q2 2026, an estimated $9.86M.
  • Enliven Therapeutics made up 0.06% of Pictet Asset Management's portfolio in Q2 2026, its #306 holding.
  • Pictet Asset Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.